Iceta, Sylvain http://orcid.org/0000-0002-0054-1865
Sohier, Léonie
Bégin, Catherine
Brazeau, Anne-Sophie
Rabasa-Lhoret, Rémi
Gagnon, Claudia
Funding for this research was provided by:
Diabetes Canada (OG-3-21-5571-SI)
Article History
Received: 30 August 2022
Accepted: 26 October 2022
First Online: 18 November 2022
Declarations
:
: This study will be performed in accordance with the Declaration of Helsinki. The ethics committee of the CHU de Québec-Université Laval approved the research protocol (reference number MP-20–2023-6466). Written informed consent will be obtained from all participants prior to study participation. Participants can withdraw from the trial at any time without providing reasons.
: Not applicable.
: S Iceta has received research grants from Takeda; has been a consultant or member on advisory panels for Takeda and Bausch Health; has received research grants from Diabetes Canada; and has received honoraria for a conference sponsored by Takeda, CCRN and Bausch Health. C. Bégin has received honoraria for a conference sponsored by Takeda and Bausch Health. A-S Brazeau has received honoraria for a conference sponsored by Dexcom. R. Rabasa-Lhoret has received research grants from Diabetes Canada; Cystic Fibrosis Canada; CIHR; Janssen; JDRF; Société Francophone du Diabète; FFRD; has been a consultant or member on advisory panels for Boehringer I; INESSS; has received honoraria for conferences sponsored by Boehringer I; Tandem. R.R.L. also benefits from unrestricted grants for clinical and educational activities from Abbott, Eli Lilly, Medtronic, Merck, Novo Nordisk and Sanofi-Aventis, and holds intellectual property in the field of type 2 diabetes risk biomarkers, catheter life and the closed-loop system. C. Gagnon has received a research grant from Novo Nordisk, Takeda, Shire and Ascendis Pharma; has been a member of the advisory panel for Novo Nordisk and has received honoraria for a conference sponsored by Amgen. No other authors have any conflicts of interest to declare.